Aesica Pharmaceuticals, the global pharmaceutical contract development and manufacturing organisation (CDMO), has announced the full strategic relocation of development and clinical manufacturing services from Nottingham to Queenborough.
As a consequence, Aesica now intends to provide full manufacturing and development services at its Queenborough site with the addition of a new development centre.
From Queenborough, the company now provides API production, formulation development, clinical manufacture through to commercial scale product manufacturing.
The new development centre will be a leader in the development of solid and liquid dosage forms, including the ability to manufacture clinical drug product for Phase One to Phase Three studies.
Ian Muir, Managing Director of Aesica Pharmaceuticals, commented, ‘The move to establish this development centre at Queenborough, with such a fully aligned and comprehensive set of services, forms part of our longer term strategy to meet the future needs of the market and represents a logical evolution for our company. Indeed, it will serve to further enhance our provision of high quality services to our customers in both formulation and drug device development.’
